ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2602

Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis

Anna Maria Hoffmann-Vold1, Håvard Fretheim 2, Brian Chung 3, Henriette Didriksen 3, Espen Bækkevold 3, Øyvind Midtvedt 3, Cathrine Brunborg 3, Kristian Holm 3, Anders Tennøe 3, Torhild Garen 3, Tore Midtvedt 4, Marius Trøseid 3, Johannes Hov 3, Knut Lundin 3 and Øyvind Molberg 2, 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 2University Hospital Oslo, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Karolinska University Hospital, Stockholm, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: microbiome and gastrointestinal complications, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In the double-blind, placebo-controlled 16-week pilot including 10 systemic sclerosis (SSc) patients with upper and lower gastrointestinal (GI) symptoms we found that fecal microbiota transplantation (FMT) with commercially-available anaerobic cultivated human intestinal microbiota (ACHIM) reduced lower GI symptoms. Here, we aimed to determine relative abundance of gut microbiota at baseline and changes after FMT.

Methods: Gastroduodenoscopy transfer of ACHIM or placebo was performed at weeks 0 and 2; fecal material was collected at week 0, 4 and 16. Relative abundance of total, immunoglobulin (Ig) A- and IgM-coated fecal bacteria was measured by 16s rRNA sequencing at week 0, 4 and 16. Relative abundance and taxonomic profiles were computed, alpha diversity and beta diversity were determined. Linear mixed models analysis were used to estimate changes in the microbiota composition and in IgA and IgM coating patterns over the entire follow-up period (i.e. baseline, 4 weeks, and 16 weeks).

Results: At baseline (week 0), there were no significant differences in fecal bacteria composition between the FMT (n=5) and placebo (n=4) groups, as measured by alpha and beta diversity. At week 16, but not at week 4, we identified differences in fecal bacteria composition between the FMT and placebo groups by the beta diversity (p< 0.02). The relative abundances of several genera changed at weeks 4 and 16 in the FMT group (Figure 1). The relative abundance of three bacterial families (Ruminococcaceae, Lachnospiraceae and Eggerthellaceae), which are dominant in ACHIM, increased post-intervention, consistent with engraftment after FMT. To assess if FMT triggered adaptive immunity in patients with SSc, we sorted and sequenced IgA and IgM coated bacteria from fecal samples and compared relative coating amongst FMT and placebo. Relative abundance of IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo (Figure 2 A and B). Some of the bacteria that were found to change their IgM coating pattern after FMT, like the genera Parabacteroides, Anaerostipes and Escherichia-Shigella, were present in the in vitro cultured fecal microbiota. Some of the bacteria which have previously been associated with other auto-immune diseases or pro-inflammatory status (Coprococcus, Roseburia, Dialister and Anaerostipes) were altered in their IgA coating patterns after FMT.

Conclusion: These observations support the notion of dynamic and ongoing immune responses to gut bacteria, and indicate that acquisition of a different gut microbiota induce immunological changes, as reflected by alterations in the pattern and/or extent of IgA and IgM coating. As mentioned above ACHIM reduced lower GI symptoms in patients with SSc. A possible link between the present observation and improved intestinal functions with ACHIM will be further studied in an upcoming investigation.

Figure 1: Relative abundance of unsorted -total- bacteria. Only bacteria with change -p<0.1- in relative abundance of unsorted bacteria from week 0-4 or week 0-16 are shown.

Figure 2A: Relative abundance of IgA coated bacteria. Only bacteria with changes -p<0.1- in relative abundance of IgA coating from week 0-4 or week 0-16 are shown.

Figure 2B: Relative abundance of IgM coated bacteria. Only bacteria with change -p<0.1- in relative abundance of IgM coating from week 0-4 or week 0-16 are shown.


Disclosure: A. Hoffmann-Vold, Actelion, 5, 8, Boehringer Ingelheim, 2, 5, 8, GSK, 5, 8; H. Fretheim, Actelion, 9, GSK, 9; B. Chung, None; H. Didriksen, GSK, 9, Actelion, 8; E. Bækkevold, None; �. Midtvedt, ACHIM, 4; C. Brunborg, None; K. Holm, None; A. Tennøe, Actelion, 8, GSK; T. Garen, None; T. Midtvedt, ACHIM, 4; M. Trøseid, None; J. Hov, None; K. Lundin, None; �. Molberg, None.

To cite this abstract in AMA style:

Hoffmann-Vold A, Fretheim H, Chung B, Didriksen H, Bækkevold E, Midtvedt �, Brunborg C, Holm K, Tennøe A, Garen T, Midtvedt T, Trøseid M, Hov J, Lundin K, Molberg �. Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/changes-in-fecal-microbiota-composition-after-fecal-microbiota-transplantation-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-fecal-microbiota-composition-after-fecal-microbiota-transplantation-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology